newsfilter
← Latest News
GlobeNewswire·

Albireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary Atresia

– BOLD is the first, largest, and only global Phase 3 trial designed to meet regulatory agencies' requirements – On track to report topline data by the end of 2024, reinforcing Bylvay's expected position as